Phase 3
Completed N=676
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Chronic Plaque Type Psoriasis
Source: ClinicalTrials.gov NCT02074982 ↗
Enrolled (actual)
676
Serious AEs
10.9%
Results posted
Jul 2017
Primary outcomePrimary: Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16 — 79.0; 57.3 Percentage of Participants — p=<0.0001
◆ Published Evidence
Highly cited
541citations · ~49 / year
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Summary
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
Linked Publications (5)
-
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
-
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
-
Continued treatment with secukinumab is associated with high retention or regain of response.
-
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
-
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16 |
79.0; 57.3 | <0.0001 sig |
| SECONDARY Speed of Onset Based on the Percentage of Participents Achieving PASI 75 at Week 4 |
49.7; 20.6 | — |
| SECONDARY Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 52 |
74.9; 60.6 | — |
Eligibility Criteria
Inclusion Criteria
- patients with moderate to severe plaque type psoriasis for at least 6 months before randomization
- patients eligible for systemic therapy with inadequately controlled psoriasis
Exclusion Criteria
- forms of sporiasis other than plaque type psoriasis
- previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA
Other protocol-defined inclusion/exclusion criteria may apply
Data sourced from ClinicalTrials.gov (NCT02074982) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.